Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), headquartered in Marlborough, Massachusetts, is a clinical-stage biotechnology company focused on developing innovative immuno-oncology therapeutics. The company's proprietary INTASYL™ siRNA gene silencing technology is at the forefront of its efforts to enhance the effectiveness of immune cells in targeting and destroying tumor cells.
Phio's core product pipeline includes:
- PH-762: Targets the checkpoint protein PD-1 on immune cells, enhancing their ability to attack tumors. Currently in Phase 1b clinical trials, PH-762 is being tested for its efficacy in treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
- PH-804: Focuses on the suppressive immune receptor TIGIT, present on T cells and natural killer cells, to bolster immune responses against cancer.
- PH-790: Aims to silence the PD-L1 protein, which normally prevents immune cells from attacking non-harmful cells, thereby boosting the body's natural defenses against cancer.
Phio Pharmaceuticals collaborates with leading institutions such as Gustave Roussy, Medigene AG, and Helmholtz Zentrum München to advance their research and development efforts. The company's financial health, as of the latest reports, shows a cash position of $6.5 million, with a significant reduction in research and development expenses aimed at transitioning from discovery to product development.
Phio's latest updates include the presentation of new data on PH-762 at various scientific conferences and the initiation of new partnerships. These efforts underscore Phio's commitment to delivering cutting-edge cancer treatments and improving patient outcomes.
For more details, visit the company's website at www.phiopharma.com.
Phio Pharmaceuticals (NASDAQ: PHIO) has announced it will present new clinical data from its ongoing Phase 1b trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, TX from November 8-10, 2024. The presentation, titled 'INTASYL PH-762: PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinoma,' will be delivered by Dr. Mary Spellman on November 9, 2024. The company's proprietary INTASYL siRNA gene silencing technology is designed to enhance immune cells' effectiveness in killing tumor cells.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company, has announced a correction to the registration link for their upcoming presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The event, featuring CEO and Chairman Robert Bitterman, is scheduled for Wednesday, October 23, 2024, at 12 PM EDT.
Stakeholders, investors, and other interested parties are invited to register and attend this live event. The presentation will include a live Q&A session. A replay of the event will be available on the Renmark Financial Communications Inc. website. Phio Pharmaceuticals specializes in INTASYL® siRNA gene silencing technology, designed to enhance immune cells' effectiveness in killing tumor cells.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company, has announced its participation in the Renmark Financial Communications Virtual Non-deal Roadshow Series. The event will feature a presentation and live Q&A session on Wednesday, October 23, 2024, at 12 PM EDT.
Mr. Robert Bitterman, CEO and Chairman of the Board, will lead the presentation. Phio Pharmaceuticals specializes in INTASYL® siRNA gene silencing technology, designed to enhance immune cells' effectiveness in killing tumor cells.
Stakeholders, investors, and interested individuals are invited to register and attend this live event. A replay will be available on the Renmark Financial Communications Inc. website. To ensure smooth connectivity, attendees are advised to use the latest version of Google Chrome when accessing the registration link.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is presenting data on its INTASYL compound PH-894 at the ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer conference. The presentation focuses on how PH-894 improves the functionality and cytotoxicity of Natural Killer (NK) cells in fighting cancer:
1. PH-894 leads to potent and specific silencing of BRD4 in NK cells without affecting cell viability.
2. It boosts NK cell numbers by enhancing proliferation during ex vivo expansion.
3. PH-894 decreases expression of CD94, an inhibitory receptor, potentially improving cytotoxic potential.
4. It may improve NK cell efficacy in adoptive cell therapies.
5. PH-894 serves as a foundation for future NK cell-based immunotherapies.
The presentation by Melissa Maxwell is scheduled for October 16, 2024, from 8 a.m. to 6:45 p.m. ET in the FDR Ballroom.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced data showcasing its proprietary INTASYL platform and compounds. INTASYL offers precise targeting by silencing mRNA both intracellularly and extracellularly, enhancing immune responses against cancer. The technology is effective as intratumoral injections and during immune cell expansion for adoptive cell therapy, requiring no special formulations for siRNA delivery.
Key INTASYL compounds include:
- PH-762: Silences PD-1, improving therapeutic efficacy in vivo
- PH-894: Silences BRD4, enhancing tumor cell immunogenicity and inducing apoptosis
- PH-804: Silences TIGIT in NK cells, enhancing activation, cytokine release, and target cell killing
- PH-905: Silences CBLB, increasing NK cell cytotoxicity and proliferation
The data will be presented at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting in Montreal on October 8th.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company, has announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The company's CEO and Chairman of the Board, Robert Bitterman, will present on Wednesday, October 9, 2024, at 2 PM EDT.
Phio Pharmaceuticals specializes in INTASYL® siRNA gene silencing technology, designed to enhance the effectiveness of immune cells in killing tumor cells. Stakeholders, investors, and interested individuals are invited to attend this live virtual event.
To participate, attendees should register through the provided link and use the latest version of Google Chrome for optimal connectivity. A replay of the event will be available on the Renmark Financial Communications website.
Phio Pharmaceuticals (NASDAQ: PHIO) announced its upcoming presentation at the American Society of Gene & Cell Therapy's 2024 Advancing Gene + Cell Therapies for Cancer conference. The event will be held virtually and in Philadelphia on October 16-17, 2024.
The presentation will focus on Phio's INTASYL compound PH-894, which targets BRD4 to enhance Natural Killer (NK) cell-based immunotherapy. Specifically, PH-894 silences BRD4 and enhances activation and proliferation of NK cells for Adoptive Cell Therapy (ACT).
Presentation details:
- Title: INTASYL PH-894: Targeting BRD4 to Enhance NK Cell-Based Immunotherapy
- Presenter: Melissa Maxwell
- Date: October 16, 2024
- Time: 8 a.m. - 6:45 p.m. ET
- Location: FDR Ballroom, Wyndham Hotel, Philadelphia Historic District
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced it will present data on its INTASYL technology platform at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting in Montreal from October 6th-9th. The presentation, titled 'INTASYL Self-Delivering RNAi: a Flexible Platform for Cancer Treatment', will focus on how INTASYL can enhance ex vivo expansion processes to improve functionality and outcomes of adoptive cell therapies like NK, TIL, or CAR-T.
INTASYL's advantage lies in its simplified chemical composition, designed to reduce toxicity and improve tolerability and efficacy in therapeutic development. The poster presentation (Number P180) will be given by Melissa Maxwell on October 8th from 3:45-6:45 PM at the Centre Mont-Royal in Montreal.
Phio Pharmaceuticals (NASDAQ: PHIO), a clinical stage biotechnology company, has announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The event is scheduled for Tuesday, September 24, 2024, at 12 PM EDT.
Mr. Robert Bitterman, CEO and Chairman of the Board, will present on behalf of Phio Pharmaceuticals. The company specializes in INTASYL® siRNA gene silencing technology, designed to enhance immune cells' effectiveness in killing tumor cells.
Stakeholders, investors, and interested individuals are invited to register and attend this live event. A replay will be available on the Renmark Financial Communications Inc. website. Attendees are advised to use the latest version of Google Chrome for optimal connectivity.
Phio Pharmaceuticals (NASDAQ: PHIO) announced a presentation at the 9th Annual CAR-TCR Summit in Boston, MA, showcasing its INTASYL self-delivering RNAi technology. The presentation, titled 'INTASYL Self-Delivering RNAi: A Flexible Platform to Improve Adoptive Cell Therapy,' will be given by Melissa Maxwell on September 17th. INTASYL is designed to enhance cell potency and yield in Adoptive Cell Therapy, potentially offering a more effective approach for cancer treatment. The technology aims to make immune cells more effective in killing tumor cells through gene silencing. This presentation highlights Phio's efforts to advance its innovative platform in the competitive field of cell therapy.
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
What does Phio Pharmaceuticals Corp. do?
What is INTASYL™ technology?
What are Phio's key products?
Who are Phio's collaboration partners?
What recent achievements has Phio Pharmaceuticals announced?
What is the financial condition of Phio Pharmaceuticals?
What is PH-762?
What cancers is PH-762 being tested for?
What is the significance of INTASYL™ technology?
Where can I find more information about Phio Pharmaceuticals?
